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Abstract—In this paper, the study of the robustness
of the positive control law introduced in [1] in the pres-
ence of parameter uncertainties is made. This controller
was developed to track a desired reference level for the
BIS of a patient by means of the simultaneous adminis-
tration of propofol and of remifentanil. Here, it is proven
that in the presence of uncertainties in the BIS model,
the controller still has a good performance and the BIS
of the patient converges to clinically acceptable values.
These results are illustrated by simulations.
I. Introduction
General anesthesia has three components: neuromuscular
blockade, analgesia and hypnosis. These two latter
components constitute the depth of anesthesia (DoA),
which may be measured ([2], [3], [4], [5], [6]) by the
Bispectral index (BIS). The BIS is a neurophysiologic
value obtained through electroencephalogram analysis,
ranged from 0 (no brain activity) to 97.7 (patient
completely awake). Usually the clinical desired BIS level
is defined within an interval, according to the clinical
surgical procedure.
A nonlinear automatic positive control law to track
a desired BIS level, by means of the administration of
the analgesic remifentanil and the hipnotic propofol,
was designed in [1]. This controller, already successfully
implemented in clinical environment, is based on the
parameter parsimonious model (PPM) (see [7]). As the
identification of the model parameters influences the
performance of this control law, a method for parameter
identification was developed in [8]. The problems raised
by the presence of uncertainties in the parameters of
the nonlinear part of the PPM was studied in [9] and a
retuning strategy in order to overcome this problem was
developed in [10].
Here, it is proven that in the presence of uncertainties in
the parameters of the linear part of the BIS model, the
controller still has a good performance and the BIS of the
patient converges to clinically acceptable values. These
results are illustrated by simulations.
The structure of this paper is as follows. Section 2 is
devoted to the explanation of the PPM while the control
law is presented in Section 3. In Section 4 the theoretical
study of the robustness of the controller in the presence
of parameter uncertainties is made. Simulation results
are presented in Section 5 and conclusions are drawn in
Section 6.
II. Model description
The patient BIS response to the administration of propofol
and of remifentanil has been recently modeled in [7] by a
Wiener model with a small number of parameters, known
as parameter parsimonious model (PPM). According to
this model, the linear relations between the propofol and
remifentanil dosages and the corresponding e ect concen-
trations (cpe and cre) are modeled by the transfer functions:
Hp(s) = k1k2k3–
3
(k1–+ s)(k2–+ s)(k3–+ s)
up(s), (1)
Hr(s) = l1l2l3÷
3
(l1÷ + s)(l2÷ + s)(l3÷ + s)
ur(s), (2)
respectively, where – and ÷ are patient dependent param-
eters, without any physiological meaning, and up(s) and
ur(s) are the Laplace transforms of the administered doses
of propofol, up(t), and of remifentanil, ur(t), in mgmin≠1.
The corresponding BIS level, z(t), usually given by the
generalized Hill equation [11], is approximated in [7] by
the nonlinear equation:
z(t) = z0
1 + (µ c
p
e
ECp50
+ creECr50 )
“
, (3)
where µ and “ are patient dependent parameters, without
any physiological meaning, z0 is the BIS level at zero
concentration, and ECp50 and ECr50 respectively denote
the propofol and remifentanil concentrations that produce
half the maximal e ect when the drug acts isolated. The
parameters ECp50 and ECr50 are taken to be fixed, namely
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ECp50 = 10 mg/ml and ECr50 = 0.01 mg/ml. These values
were obtained in the work developed in [12], to which we
refer for further explanation.
The controller considered in this paper is based on
state space methods, which implies taking state space
realizations of the transfer functions Hp(s) and Hr(s).
Here, we respectively realize these transfer functions by
means of the state space models  p = (Ap, Bp, Cp) and
 r = (Ar, Br, Cr), where
Ap =
SU ≠10– 0 09– ≠9– 0
0 – ≠–
TV ,
Bp =
SU 10–0
0
TV , Cp = # 0 0 1 $ ,
Ar =
SU ≠3÷ 0 02÷ ≠2÷ 0
0 ÷ ≠÷
TV ,
Br =
SU 3÷0
0
TV , Cr = # 0 0 1 $ .
(4)
The states of  p and of  r are respectively denoted
by xp and xr; the third components of these vectors
correspond to the e ect concentrations of propofol and of
remifentanil, respectively, whereas the other components
have no physiological meaning. The specific form of the
realizations  p and  r was chosen so as to have state
space systems with a compartmental structure. As should
be seen, this has the advantage of allowing the use of the
positive control law defined in the next section.
This yields the following equations:Y_______]_______[
x˙(t) = Ax(t) +Bu(t)5
cpe(t)
cre(t)
6
=
5
0 0 1 0 0 0
0 0 0 0 0 1
6
x(t)
z(t) = z(t) = z0
1+(µ c
p
e
EC
p
50
+ c
r
e
ECr50
)“
,
(5)
with
x =
5
xp
xr
6
, (6)
A =
5
Ap 0
0 Ar
6
and (7)
B =
5
Bp 0
0 Br
6
, (8)
where the entries 0 should be interpreted as null sub-
matrices of adequate dimensions.
III. Depth of anesthesia controller
In order to track a desired reference value for the BIS level,
by means of simultaneous administration of propofol and
of remifentanil, a nonlinear controller was presented in [1]
(see also [13]). This controller results from a combination
of a linear control law with a positivity constraint for the
drug doses. More concretely, the controller is defined by:
u(t) =
5
up(t)
ur(t)
6
=
5
max(0, u˜p(t)
max(0, u˜r(t)
6
, (9)
where up is the input of propofol and ur is the input of
remifentanil, with:5
u˜p
u˜r
6
= u˜ = E (≠KAx+ ⁄(Mú ≠Kx)) , (10)
and
E =
5
fl
1
6 1
–fl+ 300÷ , (11)
Mú = mfl,µ
1 z0
zú
≠ 1
2 1
“
, (12)
mfl,µ =
3(0.1fl+ 100)
0.1µfl+ 100 (13)
K =
#
0.1 0.1 0.1 100 100 100
$
, (14)
zú is the desired BIS level, and ⁄ and fl are positive
design parameters that do not a ect the tracked reference
value and can be chosen according to clinical criteria.
The parameter ⁄ influences the convergence speed to
the desired reference value and the parameter fl can be
interpreted as the proportion between the doses of propofol
and remifentanil.
Note that the matrix E is such that
KBE = 1. (15)
For more details about this controller and its tracking
properties, the reader is referred to [1].
IV. DoA controller robustness
In this section, the robustness of the control law (9) under
the presence of uncertainties in the parameters of the
linear part of the PPM is analyzed. The description of the
controller action under parameter uncertainties is made
in the next subsection and its robustness is studied in the
following one.
A. Controller with uncertainties
In practice, the true values of – and ÷ of the PPM are
unknown and estimated values –ˆ and ÷ˆ are used instead.
This means that estimated control doses uˆp of propofol and
uˆr of remifentanil are used. These doses are computed as
5
uˆp(t)
uˆr(t)
6
= uˆ(t) = uˆ(x(t)) =
5
max(0, ˆ˜up(t)
max(0, ˆ˜ur(t)
6
, (16)
with:
ˆ˜u =
5 ˆ˜up
ˆ˜ur
6
= Eˆ
1
≠KAˆx+ ⁄(Mú ≠Kx)
2
, (17)
where
Aˆ =
SWWWWWWU
≠10–ˆ 0 0 0 0 0
9–ˆ ≠9–ˆ 0 0 0 0
0 –ˆ ≠–ˆ 0 0 0
0 0 0 ≠3÷ˆ 0 0
0 0 0 2÷ˆ ≠2÷ˆ 0
0 0 0 0 ÷ˆ ≠÷ˆ
TXXXXXXV , (18)
and
Eˆ =
5
fl
1
6 1
–ˆfl+ 300÷ˆ ,
For technical reasons we define
k = –fl+ 300÷
–ˆfl+ 300÷ˆ (19)
and write the matrix Eˆ as:
Eˆ = Ek. (20)
Then ˆ˜u may be written as
ˆ˜u = ˆ˜u(x) = Eˆk
1
≠KAˆx+ ⁄(Mú ≠Kx)
2
. (21)
B. Robustness analysis
In order to study the robustness of the DoA controller un-
der parameter uncertainty, the following auxiliary output
is considered:
M(x) = Kx. (22)
It was proven in [1] that if in steady state M(x) = M¯ ,
then the steady state BIS of the patient, z¯, is equal to
z¯ =
Qccca z0
1 +
3
M¯
mfl,µ
4“
Rdddb . (23)
This implies that, when M(x) converges to Mú (as
in equation (12)), the BIS of the patient converges to the
reference value zú.
Since there is a relation between the output M(x)
and the BIS of the patient, in a first step, the influence
of the parameter uncertainties on the auxiliary output
M(x) is studied. More concretely, we shall prove that,
for suitable values of the design parameter ⁄, when the
estimated control law (16) is applied to the PPM given
by (5) with true parameters – and —, M(x) converges to
an interval IM , which contains Mú. For this purpose we
define:
 – = –≠ –ˆ, r = max{8–ˆ, ÷ˆ}, (24)
 ÷ = ÷ ≠ ÷ˆ, s = max{|8 –|, | ÷|}, (25)
and  KA = KA≠KAˆ.
Taking into account that:
KAˆ = ≠ # 0.1–ˆ 0.1(8–ˆ) 0.1–ˆ 100÷ˆ 100÷ˆ 100÷ˆ $ ,
(26)
and that
 KA = (27)
≠ [ 0.1 – 0.1(8 –) 0.1 – 100 ÷ 100 ÷ 100 ÷ ] ,
the following inequalities, that will be useful later on, hold:
|KAˆ|x Æ rKx = rM(x); (28)
| KA|x Æ sKx = rM(x). (29)
Let
IM =
#
M¯min , M¯max
$
, (30)
with
M¯min =
k⁄
k⁄+ ks
Mú, (31)
M¯max =
k⁄
k⁄≠ ksM
ú, (32)
 ks = |1≠ k|r + s. (33)
(34)
We next prove that M(x) converges to IM . For this
purpose, we apply the LaSalle’s invariance principle (see
[14]) to the Lyapunov function V : Rn ≠æ R defined by:
V (x) =
Y][
1
2 (M(x)≠ M¯min)2 ifM(x) < M¯min1
2 (M(x)≠ M¯max)2 ifM(x) > M¯max
0 otherwise.
(35)
V (x) is a LaSalle-Lyapunov function of the system
on Rn+ because it is continuous and its time derivative
along the close-loop system trajectories, V˙ (x), satisfies
V˙ (x) Æ 0, ’x œ Rn+, as shown next. Indeed, V˙ (x) is given
by:
V˙ (x) =
Y][ (M(x)≠ M¯min)M˙ ifM(x) < M¯min(M(x)≠ M¯max)M˙ ifM(x) > M¯max0 otherwise, (36)
with M˙(x) = Kx˙ = KAx+KBuˆ.
The study of the non positivity of V˙ is divided into
two cases. First we consider M(x) < M¯min and prove
that in this case M(x) > 0, implying that V˙ < 0. Second,
we analyze the case when M(x) > M¯max and verify that
in this case M(x) < 0 and then V˙ < 0, as well.
Case one - M(x) < M¯min
When M(x) < M¯min, M(x) < Mú, and consequently
ˆ˜u > 0. Then uˆ = ˆ˜u and M˙(x) becomes:
M˙(x) = KAx+KB ˆ˜u (37)
= KAx+KBE¸ ˚˙ ˝
1
k(≠KAˆx+ ⁄(Mú ≠M(x)) (38)
= KAx≠ kKAˆx+ k⁄(Mú ≠M(x))) (39)
= KAˆx+ KAx≠ kKAˆx+ k⁄(Mú ≠M(x)) (40)
= (1≠ k)KAˆx+ KAx+ k⁄(Mú ≠M(x)) (41)
Ø ≠|1≠ k||KAˆ|x≠ | KA|x+ k⁄(Mú ≠M(x))
(42)
Ø ≠|1≠ k|rM(x)≠ sM(x) + k⁄(Mú ≠M(x))
(43)
= ≠|1≠ k|rM(x)≠ sM(x) + k⁄Mú ≠ k⁄M(x)
(44)
= k⁄Mú ≠ (k⁄+ |1≠ k|r + s)M(x) (45)
= k⁄Mú ≠ (k⁄+ ks)M(x) (46)
= (k⁄+ ks)
3
k⁄
k⁄+ ks
Mú ≠M(x)
4
(47)
= (k⁄+ ks)
!
M¯min ≠M(x)
"
> 0. (48)
The relation between expressions (41) and (42) is due to
the fact that every a œ R satisfies a Ø ≠|a|, whereas the
relation between expressions (42) and (43) results from
(28) and (29).
Case two - M(x) > M¯max
Let M(x) > M¯max. If ˆ˜u < 0, then uˆ = 0 and
M˙(x) = KAx (49)
= ≠ # 0.1– 0.8– 0.1– 100÷ 100÷ 100÷ $x
Æ 0,
because all the components of x are nonnegative. If ˆ˜u > 0,
then uˆ = ˆ˜u and M˙(x) becomes (see equation (41)):
M˙(x) = (1≠ k)KAˆx+ KAx+ k⁄(Mú ≠M(x)) (50)
Æ |1≠ k||KAˆ|x+ | KA|x+ k⁄(Mú ≠M(x)) (51)
Æ |1≠ k|rM(x) + sM(x) + k⁄(Mú ≠M(x)) (52)
= |1≠ k|rM(x) + sM(x) + k⁄Mú ≠ k⁄M(x) (53)
= k⁄Mú ≠ (k⁄≠ |1≠ k|r ≠ s)M(x) (54)
= k⁄Mú ≠ (k⁄≠ ks)M(x) (55)
= (k⁄≠ ks)
3
k⁄
k⁄≠ ksM
ú ≠M(x)
4
(56)
= (k⁄≠ ks)
!
M¯max ≠M(x)
"
< 0, (57)
for k⁄ > | ks|.
Thus V˙ (x) is indeed nonpositive, provided that the
value of the design parameter ⁄ is taken larger than
| ks|
k , and by the LaSalle’s invariance principle, all system
trajectories, x(t), converge to the largest set contained in
W = {x œ Rn+ : V˙ (x) = 0}, (58)
which is forward-invariant under the closed-loop dynamics.
It follows from (36) that V˙ (x) = 0 either when u = u˜
and (M(x) = M¯min or M(x) = M¯max or M(x) =
(1≠k)KAˆx+ KAx+k⁄Mú
k⁄ ), or when u = 0, which implies that
M(x) > Mú, and KAx = 0. So we get
W =I1 fi I2 fi I3 fi I4 with (59)
I1 ={x œ Rn+ :M(x) = M¯min and ˆ˜u(x) > 0} (60)
I2 ={x œ Rn+ :M(x) = M¯max and ˆ˜u(x) > 0} (61)
I3 ={x œ Rn+ :M(x) =
(1≠ k)KAˆx+ KAx
k⁄
+Mú and ˆ˜u(x) > 0} (62)
I4 ={x œ Rn+ : KAx = 0 and uˆ(x) = 0}. (63)
The set I4 is not invariant. In fact, if uˆ would remain
equal to zero, at a certain time instant, M(x) would
become smaller than Mú, ˆ˜u(x) would become positive,
and uˆ(x) would equal ˆ˜u(x), so the trajectory x(t) would
leave the subset. On the other hand, both I1, I2 and I3 are
subsets of IM , which is invariant, indeed if M(x) Æ M¯min,
then M˙(x) Ø 0 and if M(x) Ø M¯max, then M˙(x) Æ 0.
Therefore, one may conclude that M(x) converges to (a
subset contained in) the interval IM as previously claimed.
Since the patient BIS response to the administered
drug doses uˆ is a decreasing function of M(x) (cf.
equation (23)), the BIS level converges to the interval:
IBIS = ]BISmin , BISmax[ , (64)
with
BISmin =
z0
1 +
3
M¯max
mfl,µ
4“ and (65)
(66)
BISmax =
z0
1 +
3
M¯min
mfl,µ
4“ . (67)
As expected, the desired steady state value zú is not
achieved, but the patient’s BIS remains in a neighborhood
of this target value. Moreover, when the errors in the
parameters go to 0, and hence s goes to 0 and k goes to 1
(see the remark below), M¯min, M¯max and M(x) converge
to Mú. This implies that the patient BIS converges to
the desired value zú, which means that the control law is
robust with respect to parameter uncertainties. Moreover,
as can be seen by expressions (31) and (32), increasing
the parameter ⁄ decreases the width of the interval IM
and consequentely the robustness of the controller is also
increased.
Remark:
Recall that:
k =–fl+ 300÷
–ˆfl+ 300÷ˆ (68)
= –ˆfl+ –fl+ 300÷ˆ + 300 ÷
–ˆfl+ 300÷ˆ (69)
=1 +  –fl+ 300 ÷
–ˆfl+ 300÷ˆ , (70)
thus, if  – and  ÷ converge to zero k clearly converges
to the value 1.
V. Simulations
In this section, the performance of the control law (9)
under the presence of uncertainties in the parameters
on the linear part of the PPM is illustrated by means
of simulations. For this purpose, a test patient was
considered modeled by a PPM with realistic parameters:
– = 0.068, ÷ = 0.337, µ = 1.14, and “ = 4.12 (see
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Fig. 1. BIS evolution in the presence of uncertainties, –ˆ = 0.5–,
÷ˆ = 0.5÷. The reference value for the BIS level was set to be 50.
[12]). On the other hand, the control law was tuned
with z0 = 97.7 and the design parameters ⁄ = 100 and
fl = 600. The desired reference value for the BIS, zú, was
set to be 50.
Figure 1 shows the BIS response of the patient using
the controller (16) tuned for estimated parameters
–ˆ = 0.5– = 0.034 and ÷ˆ = 0.5÷ = 0.1685. These values
correspond to an estimation error of 50%. As theoretically
proved, the BIS converged to the interval
IBIS = ]BISmin , BISmax[ , (71)
with BISmin = 49.7 and BISmax = 50.3. In spite of the
error of 50% in the parameters, the interval IBIS is very
narrow and the BIS nearly converged to the desired value
50.
The BIS evolution of the patient under the presence of
an error of 90% in the estimation of the parameters is
illustrated in Fig. 2. In this case, the controller (16) was
tuned for estimated parameters –ˆ = 1.9– = 0.1292 and
÷ˆ = 1.9÷ = 0.6403. As in the previous simulation, the BIS
of the patient also converged to the interval IBIS , now
with BISmin = 48.1 and BISmax = 51.8. Although the
parameter estimates presents an error of 90%, the BIS of
the patient also nearly converged to 50.
VI. Conclusion
In this paper, the robustness of the nonlinear control law
proposed in [1], in order to control the BIS level of patients
by means of simultaneous administration of propofol and
remifentanil, was studied. It was theoretically proven that
even in the presence of model uncertainties, the BIS of
the patient converges to an interval that contains the de-
sired reference value for the BIS. Moreover, the presented
simulations suggest that, under these circumstances, the
BIS also converges to a constant value within the expected
range. A study of this conjecture is the subject of ongoing
research.
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Fig. 2. BIS evolution in the presence of uncertainties, –ˆ = 1.9–,
÷ˆ = 1.9÷. The reference value for the BIS level was set to be 50
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